Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1517220 | 0.89 | KCNK3 (0.50) | MAPTHTTRAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL1516907 | 0.87 | MAPT (0.50) | MAPTHTTRAB9ASMN1; SMN2CA1 | |
| SCHEMBL16533962 | 0.84 | MAPK14 (0.56) | MAPTHTTRAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL1331266 | 0.83 | CA1 (0.57) | MAPTHTTRAB9ASMN1; SMN2CA1 | |
| SCHEMBL257797 | 0.82 | CA1 (0.68) | MAPTRAB9ASMN1; SMN2CA1CA2 | |
| SCHEMBL25272009 | 0.80 | LMNA (0.61) | MAPTHTTRAB9ACA1CA2 | |
| SCHEMBL31224954 | 0.79 | TP53 (0.57) | RAB9ASMN1; SMN2CA1CA2CA9 | |
| SCHEMBL14568092 | 0.79 | HDAC1 (0.52) | RAB9ASMN1; SMN2CA1CA2CA9 | |
| SCHEMBL14120424 | 0.78 | KMT2A (0.61) | CA1CA2CA9ALDH1A1TP53 | |
| SCHEMBL8970557 | 0.78 | KCNK3 (0.70) | MAPTHTTRAB9ASMN1; SMN2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| EP-3481831-B1 | 4-AMINOPYRAZOLO[3,4-D]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2023-09-06 | — | — | EP | disclosed |
| CN-109153680-B | 4-aminopyrazolo [3,4-d ] pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2021-04-23 | — | — | CN | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-03 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399988-B2 | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same | ITK, BTK, TYK2 | MAPT 4162/4885HTT 3440/4885RAB9A 2138/4885 |
| US-20190161488-A1 | Novel 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo Derivatives and Pharmaceutical Composition Comprising the Same | BTK, ITK, TYK2 | MAPT 4017/4885HTT 3499/4885RAB9A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.